• David St Denis appointed as Company President and Non-Independent Director
• St Denis has over 25 years of experience in the pharmaceutical industry
• Appointment effective immediately, no changes to current compensation arrangements

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) has announced the appointment of David St Denis as the Company's President and as a Class II director of the Board, effective immediately. Mr. St Denis, 56, has served as Chief Operating Officer of the Company since July 2017 and the Chief Executive Officer of v2vmedtech, inc. since April 2023. Prior to his appointment as Chief Operating Officer, Mr. St Denis held various leadership roles at Merck and Millennium Pharmaceuticals, Inc. (now Takeda Pharmaceutical Company). Mr. St Denis has a Bachelor of Science from the University of Connecticut, a Master of Arts from Boston University, and an MBA in Global Management and International Marketing from Babson College - Franklin W. Olin Graduate School of Business. As a non-independent director, Mr. St Denis will not serve on any committees of the Board. There have been no material changes to Mr. St Denis's current compensatory arrangements, nor has he received any grants or awards in connection with his appointment as President or as director of the Board.